New Insights into the Connection between Histone Deacetylases, Cell Metabolism, and Cancer

Antioxidants and Redox Signaling

Volumn 23, Issue 1, 2015, Pages 30-50

  Chiaradonna, Ferdinando ^a,b   Cirulli, Claudia ^a,b   Palorini, Roberta ^a,b   Votta, Giuseppina ^a,b   Alberghina, Lilia ^a,b  

^a SYSBIO Centre of Systems Biology   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN P53; STAT3 PROTEIN; TRANSCRIPTION FACTOR YY1; VALPROIC ACID; VORINOSTAT;

CELL METABOLISM; DIET; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME REGULATION; HISTONE ACETYLATION; HUMAN; METABOLITE; MYELOID LEUKEMIA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ACETYLATION; ANIMAL; CELL NUCLEUS; CYTOPLASM; METABOLISM; NEOPLASMS;

MUS;

ACETYLATION; ANIMALS; CELL NUCLEUS; CYTOPLASM; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS;

EID: 84934967988     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.5854     Document Type: Review

References (201)

1. Aagaard-Tillery KM, Grove K, Bishop J, Ke X, Fu Q, McKnight R, and Lane RH. Developmental origins of disease and determinants of chromatin structure: maternal diet modifies the primate fetal epigenome. J Mol Endocrinol 41: 91-102, 2008.
2. Abramson HN. The lipogenesis pathway as a cancer target. J Med Chem 54: 5615-5638, 2011.
3. Alberghina L, Gaglio D, Gelfi C, Moresco RM, Mauri G, Bertolazzi P, Messa C, Gilardi MC, Chiaradonna F, and Vanoni M. Cancer cell growth and survival as a systemlevel property sustained by enhanced glycolysis and mitochondrial metabolic remodeling. Front Physiol 3: 362, 2012.
4. Alirol E and Martinou JC. Mitochondria and cancer: is there a morphological connection? Oncogene 25: 4706-4716, 2006.
5. Amoedo ND, Rodrigues MF, Pezzuto P, Galina A, da Costa RM, de Almeida FC, El-Bacha T, and Rumjanek FD. Energy metabolism in H460 lung cancer cells: effects of histone deacetylase inhibitors. PLoS One 6: e22264, 2011.
6. Austin S and St.-Pierre J. PGC1alpha and mitochondrial metabolism - emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci 125: 4963-4971, 2012.
7. Backs J, Worst BC, Lehmann LH, Patrick DM, Jebessa Z, Kreusser MM, Sun Q, Chen L, Heft C, Katus HA, and Olson EN. Selective repression of MEF2 activity by PKA-dependent proteolysis of HDAC4. J Cell Biol 195: 403-415, 2011.
8. Beloueche-Babari M, Arunan V, Troy H, te Poele RH, te Fong AC, Jackson LE, Payne GS, Griffiths JR, Judson IR, Workman P, Leach MO, and Chung YL. Histone deacetylase inhibition increases levels of choline kinase alpha and phosphocholine facilitating noninvasive imaging in human cancers. Cancer Res 72: 990-1000, 2012.
9. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, and Vousden KH. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120, 2006.
10. Blattler SM, Verdeguer F, Liesa M, Cunningham JT, Vogel RO, Chim H, Liu H, Romanino K, Shirihai OS, Vazquez F, Ruegg MA, Shi Y, and Puigserver P. Defective mitochondrial morphology and bioenergetic function in mice lacking the transcription factor Yin Yang 1 in skeletal muscle. Mol Cell Biol 32: 3333-3346, 2012.
11. Bolden JE, Shi W, Jankowski K, Kan CY, Cluse L, Martin BP, MacKenzie KL, Smyth GK, and Johnstone RW. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis 4: e519, 2013.
12. Boxer LM and Dang CV. Translocations involving c-myc and c-myc function. Oncogene 20: 5595-5610, 2001.
13. Brahimi-Horn MC, Chiche J, and Pouyssegur J. Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 19: 223-229, 2007.
14. Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, Elstrom RL, and Thompson CB. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24: 4165-4173, 2005.
15. Cavuoto P and Fenech MF. A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension. Cancer Treat Rev 38: 726-736, 2012.
16. Chang CW, Lee L, Yu D, Dao K, Bossuyt J, and Bers DM. Acute beta-adrenergic activation triggers nuclear import of histone deacetylase 5 and delays G(q)-induced transcriptional activation. J Biol Chem 288: 192-204, 2013.
17. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, and Olson EN. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24: 8467-8476, 2004.
18. Cheng J, Wang D, Wang Z, and Yeh ET. SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol 24: 6021-6028, 2004.
19. Chiaradonna F, Gaglio D, Vanoni M, and Alberghina L. Expression of transforming K-Ras oncogene affects mitochondrial function and morphology in mouse fibroblasts. Biochim Biophys Acta 1757: 1338-1356, 2006.
20. Chiaradonna F, Moresco RM, Airoldi C, Gaglio D, Palorini R, Nicotra F, Messa C, and Alberghina L. From cancer metabolism to new biomarkers and drug targets. Biotechnol Adv 30: 30-51, 2012.
21. Chou CW, Wu MS, Huang WC, and Chen CC. HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS One 6: e18087, 2011.
22. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, and Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840, 2009.
23. Cohen I, Poreba E, Kamieniarz K, and Schneider R. Histone modifiers in cancer: friends or foes? Genes Cancer 2: 631-647, 2011.
24. Conte M and Altucci L. Molecular pathways: the complexity of the epigenome in cancer and recent clinical advances. Clin Cancer Res 18: 5526-5534, 2011.
25. Cousens LS, Gallwitz D, and Alberts BM. Different accessibilities in chromatin to histone acetylase. J Biol Chem 254: 1716-1723, 1979.
26. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, and Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 450: 736-740, 2007.
27. Czubryt MP, McAnally J, Fishman GI, and Olson EN. Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. Proc Natl Acad Sci U S A 100: 1711-1716, 2003.
28. Dang CV, Le A, and Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 15: 6479-6483, 2009.
29. DeAngelis RA, Markiewski MM, Taub R, and Lambris JD. A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-kappaB inhibitor, IkappaBalpha. Hepatology 42: 1148-1157, 2005.
30. DeBerardinis RJ and Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29: 313-324, 2010.
31. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, and Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20, 2008.
32. Demaria M, Giorgi C, Lebiedzinska M, Esposito G, D'Angeli L, Bartoli A, Gough DJ, Turkson J, Levy DE, Watson CJ, Wieckowski MR, Provero P, Pinton P, and Poli V. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) 2: 823-842, 2010.
33. Dewhirst MW, Cao Y, and Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8: 425-437, 2008.
34. Donohoe DR, Collins LB, Wali A, Bigler R, Sun W, and Bultman SJ. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell 48: 612-626, 2012.
35. Dowling DP, Gattis SG, Fierke CA, and Christianson DW. Structures of metal-substituted human histone deacetylase 8 provide mechanistic inferences on biological function. Biochemistry 49: 5048-5056, 2010.
36. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, and Manning BD. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39: 171-183, 2010.
37. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, and Thompson CB. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899, 2004.
38. Faiola F, Liu X, Lo S, Pan S, Zhang K, Lymar E, Farina A, and Martinez E. Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription. Mol Cell Biol 25: 10220-10234, 2005.
39. Fang X, Yu SX, Lu Y, Bast RC, Jr., Woodgett JR, and Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 97: 11960-11965, 2000.
40. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, Mamer OA, Avizonis D, DeBerardinis RJ, Siegel PM, and Jones RG. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 17: 113-124, 2013.
41. Ferber EC, Peck B, Delpuech O, Bell GP, East P, and Schulze A. FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression. Cell Death Differ 19: 968-979, 2011.
42. Fischer DD, Cai R, Bhatia U, Asselbergs FA, Song C, Terry R, Trogani N, Widmer R, Atadja P, and Cohen D. Isolation and characterization of a novel class II histone deacetylase, HDAC10. J Biol Chem 277: 6656-6666, 2002.
43. Fischle W, Dequiedt F, Fillion M, Hendzel MJ, Voelter W, and Verdin E. Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem 276: 35826-35835, 2001.
44. Frank SR, Parisi T, Taubert S, Fernandez P, Fuchs M, Chan HM, Livingston DM, and Amati B. MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep 4: 575-580, 2003.
45. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, Borresen-Dale AL, Levine AJ, Bargonetti J, and Prives C. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148: 244-258, 2012.
46. Galmozzi A, Mitro N, Ferrari A, Gers E, Gilardi F, Godio C, Cermenati G, Gualerzi A, Donetti E, Rotili D, Valente S, Guerrini U, Caruso D, Mai A, Saez E, De Fabiani E, and Crestani M. Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. Diabetes 62: 732-742, 2012.
47. Gan YH and Zhang S. PTEN/AKT pathway involved in histone deacetylases inhibitor induced cell growth inhibition and apoptosis of oral squamous cell carcinoma cells. Oral Oncol 45: e150-e154, 2009.
48. Gao C, Dimitrov T, Yong KJ, Tatetsu H, Jeong HW, Luo HR, Bradner JE, Tenen DG, and Chai L. Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. Blood 121: 1413-1421, 2013.
49. Gao L, Cueto MA, Asselbergs F, and Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277: 25748-25755, 2002.
50. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, and Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18: 7185-7191, 1998.
51. Geng H, Harvey CT, Pittsenbarger J, Liu Q, Beer TM, Xue C, and Qian DZ. HDAC4 protein regulates HIF1alpha protein lysine acetylation and cancer cell response to hypoxia. J Biol Chem 286: 38095-38102, 2011.
52. Georgescu MM. PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer 1: 1170-1177, 2010.
53. Glozak MA and Seto E. Histone deacetylases and cancer. Oncogene 26: 5420-5432, 2007.
54. Gordon S, Akopyan G, Garban H, and Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 25: 1125-1142, 2006.
55. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, and Levy DE. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324: 1713-1716, 2009.
56. Gray SG, Qian CN, Furge K, Guo X, and Teh BT. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol 24: 773-795, 2004.
57. Gregoretti IV, Lee YM, and Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338: 17-31, 2004.
58. Gross DN, van den Heuvel AP, and Birnbaum MJ. The role of FoxO in the regulation of metabolism. Oncogene 27: 2320-2336, 2008.
59. Grozinger CM and Schreiber SL. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci U S A 97: 7835-7840, 2000.
60. Gu W and Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606, 1997.
61. Gupta M, Han JJ, Stenson M, Wellik L, and Witzig TE. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 26: 1356-1364, 2012.
62. Haberland M, Mokalled MH, Montgomery RL, and Olson EN. Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev 23: 1625-1630, 2009.
63. Haberland M, Montgomery RL, and Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10: 32-42, 2009.
64. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, Luo C, Marmorstein R, Kordula T, Milstien S, and Spiegel S. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 325: 1254-1257, 2009.
65. Hardie DG and Alessi DR. LKB1 and AMPK and the cancer-metabolism link-ten years after. BMC Biol 11: 36, 2013.
66. Harms KL and Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 67: 3145-3152, 2007.
67. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
68. Harrison BC, Huynh K, Lundgaard GL, Helmke SM, Perryman MB, and McKinsey TA. Protein kinase C-related kinase targets nuclear localization signals in a subset of class IIa histone deacetylases. FEBS Lett 584: 1103-1110, 2010.
69. Hassig CA, Tong JK, and Schreiber SL. Fiber-derived butyrate and the prevention of colon cancer. Chem Biol 4: 783-789, 1997.
70. Hebert AS, Dittenhafer-Reed KE, Yu W, Bailey DJ, Selen ES, Boersma MD, Carson JJ, Tonelli M, Balloon AJ, Higbee AJ, Westphall MS, Pagliarini DJ, Prolla TA, Assadi-Porter F, Roy S, Denu JM, and Coon JJ. Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. Mol Cell 49: 186-199, 2013.
71. Heruth DP, Zirnstein GW, Bradley JF, and Rothberg PG. Sodium butyrate causes an increase in the block to transcriptional elongation in the c-myc gene in SW837 rectal carcinoma cells. J Biol Chem 268: 20466-20472, 1993.
72. Hervouet E, Demont J, Pecina P, Vojtiskova A, Houstek J, Simonnet H, and Godinot C. A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesis. Carcinogenesis 26: 531-539, 2005.
73. Huang H, Liu N, Guo H, Liao S, Li X, Yang C, Liu S, Song W, Liu C, Guan L, Li B, Xu L, Zhang C, Wang X, Dou QP, and Liu J. L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro. PLoS One 7: e49062, 2012.
74. Ismail HM, Myronova O, Tsuchiya Y, Niewiarowski A, Tsaneva I, and Gout I. Identification of the general transcription factor Yin Yang 1 as a novel and specific binding partner for S6 kinase 2. Cell Signal 25: 1054-1063, 2013.
75. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, and Yao TP. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 21: 6236-6245, 2002.
76. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish CB, and Mootha VK. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336: 1040-1044, 2012.
77. Jaitovich A and Bertorello AM. Intracellular sodium sensing: SIK1 network, hormone action and high blood pressure. Biochim Biophys Acta 1802: 1140-1149, 2010.
78. Jensen J, Rustad PI, Kolnes AJ, and Lai YC. The role of skeletal muscle glycogen breakdown for regulation of insulin sensitivity by exercise. Front Physiol 2: 112, 2011.
79. Jiang P, Du W, Mancuso A, Wellen KE, and Yang X. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 493: 689-693, 2013.
80. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M, and Yang X. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 13: 310-316, 2011.
81. Joensuu T and Mester J. Inhibition of cell cycle progression by sodium butyrate in normal rat kidney fibroblasts is altered by expression of the adenovirus 5 early 1A gene. Biosci Rep 14: 291-300, 1994.
82. Joshi P, Greco TM, Guise AJ, Luo Y, Yu F, Nesvizhskii AI, and Cristea IM. The functional interactome landscape of the human histone deacetylase family. Mol Syst Biol 9: 672, 2013.
83. Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS, and Wu CW. Histone deacetylases specifically downregulate p53-dependent gene activation. J Biol Chem 275: 20436-20443, 2000.
84. Kaelin WG, Jr., and McKnight SL. Influence of metabolism on epigenetics and disease. Cell 153: 56-69, 2013.
85. Kato H, Tamamizu-Kato S, and Shibasaki F. Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem 279: 41966-41974, 2004.
86. Kelly RD and Cowley SM. The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem Soc Trans 41: 741-749, 2013.
87. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW, and Kim KW. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7: 437-443, 2001.
88. Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J, Cheng T, Kho Y, Xiao H, Xiao L, Grishin NV, White M, Yang XJ, and Zhao Y. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23: 607-618, 2006.
89. Kirsh O, Seeler JS, Pichler A, Gast A, Muller S, Miska E, Mathieu M, Harel-Bellan A, Kouzarides T, Melchior F, and Dejean A. The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J 21: 2682-2691, 2002.
90. Kitano H. Systems biology: a brief overview. Science 295: 1662-1664, 2002.
91. Knutson SK, Chyla BJ, Amann JM, Bhaskara S, Huppert SS, and Hiebert SW. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J 27: 1017-1028, 2008.
92. Kong X, Lin Z, Liang D, Fath D, Sang N, and Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 26: 2019-2028, 2006.
93. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH, and Burgering BM. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419: 316-321, 2002.
94. Kou XX, Hao T, Meng Z, Zhou YH, and Gan YH. Acetylated Sp1 inhibits PTEN expression through binding to PTEN core promoter and recruitment of HDAC1 and promotes cancer cell migration and invasion. Carcinogenesis 34: 58-67, 2013.
95. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, and Yao TP. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18: 601-607, 2005.
96. Kretzner L, Scuto A, Dino PM, Kowolik CM, Wu J, Ventura P, Jove R, Forman SJ, Yen Y, and Kirschbaum MH. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res 71: 3912-3920, 2011.
97. Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16: 202-208, 2000.
98. Kurland JF and Tansey WP. Myc-mediated transcriptional repression by recruitment of histone deacetylase. Cancer Res 68: 3624-3629, 2008.
99. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, and Seiser C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 21: 2672-2681, 2002.
100. Laplante M and Sabatini DM. Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci 126: 1713-1719, 2013.
101. Latham T, Mackay L, Sproul D, Karim M, Culley J, Harrison DJ, Hayward L, Langridge-Smith P, Gilbert N, and Ramsahoye BH. Lactate, a product of glycolytic metabolism, inhibits histone deacetylase activity and promotes changes in gene expression. Nucleic Acids Res 40: 4794-4803, 2012.
102. Lazo PA. Amino acids and glucose utilization by different metabolic pathways in ascites-tumour cells. Eur J Biochem 117: 19-25, 1981.
103. Lee H, Rezai-Zadeh N, and Seto E. Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol Cell Biol 24: 765-773, 2004.
104. Li DQ, Pakala SB, Nair SS, Eswaran J, and Kumar R. Metastasis-associated protein 1/nucleosome remodeling and histone deacetylase complex in cancer. Cancer Res 72: 387-394, 2012.
105. Liang J and Mills GB. AMPK: a contextual oncogene or tumor suppressor? Cancer Res 73: 2929-2935, 2013.
106. Lin R, Zhou X, Huang W, Zhao D, Lv L, Xiong Y, Guan KL, and Lei QY. Acetylation control of cancer cell metabolism. Curr Pharm Des 13: 1-7, 2013.
107. Lin YY, Kiihl S, Suhail Y, Liu SY, Chou YH, Kuang Z, Lu JY, Khor CN, Lin CL, Bader JS, Irizarry R, and Boeke JD. Functional dissection of lysine deacetylases reveals that HDAC1 and p300 regulate AMPK. Nature 482: 251-255, 2012.
108. Luo J, Su F, Chen D, Shiloh A, and Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408: 377-381, 2000.
109. Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H, Zha Z, Liu Y, Li Z, Xu Y, Wang G, Huang Y, Xiong Y, Guan KL, and Lei QY. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 42: 719-730, 2011.
110. Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 19: 1049-1066, 2010.
111. Marks PA, Richon VM, Miller T, and Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 91: 137-168, 2004.
112. Marshall GM, Gherardi S, Xu N, Neiron Z, Trahair T, Scarlett CJ, Chang DK, Liu PY, Jankowski K, Iraci N, Haber M, Norris MD, Keating J, Sekyere E, Jonquieres G, Stossi F, Katzenellenbogen BS, Biankin AV, Perini G, and Liu T. Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene 29: 5957-5968, 2010.
113. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, and Hwang PM. p53 regulates mitochondrial respiration. Science 312: 1650-1653, 2006.
114. McBrian MA, Behbahan IS, Ferrari R, Su T, Huang TW, Li K, Hong CS, Christofk HR, Vogelauer M, Seligson DB, and Kurdistani SK. Histone acetylation regulates intracellular pH. Mol Cell 49: 310-321, 2013.
115. McGee SL, van Denderen BJ, Howlett KF, Mollica J, Schertzer JD, Kemp BE, and Hargreaves M. AMP-activated protein kinase regulates GLUT4 transcription by phosphorylating histone deacetylase 5. Diabetes 57: 860-867, 2008.
116. Michalopoulos GK. Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. Am J Pathol 176: 2-13, 2010.
117. Mihaylova MM and Shaw RJ. Metabolic reprogramming by class I and II histone deacetylases. Trends Endocrinol Metab 24: 48-57, 2013.
118. Mihaylova MM, Vasquez DS, Ravnskjaer K, Denechaud PD, Yu RT, Alvarez JG, Downes M, Evans RM, Montminy M, and Shaw RJ. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 145: 607-621, 2011.
119. Minucci S and Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51, 2006.
120. Mizuno S, Iijima R, Ogishima S, Kikuchi M, Matsuoka Y, Ghosh S, Miyamoto T, Miyashita A, Kuwano R, and Tanaka H. AlzPathway: a comprehensive map of signaling pathways of Alzheimer's disease. BMC Syst Biol 6: 52, 2012.
121. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X, Hill JA, Richardson JA, and Olson EN. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 21: 1790-1802, 2007.
122. Montgomery RL, Potthoff MJ, Haberland M, Qi X, Matsuzaki S, Humphries KM, Richardson JA, Bassel-Duby R, and Olson EN. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 118: 3588-3597, 2008.
123. Morad SA and Cabot MC. Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer 13: 51-65, 2013.
124. Mosley AL and Ozcan S. The pancreatic duodenal homeobox-1 protein (Pdx-1) interacts with histone deacetylases Hdac-1 and Hdac-2 on low levels of glucose. J Biol Chem 279: 54241-54247, 2004.
125. Nishino TG, Miyazaki M, Hoshino H, Miwa Y, Horinouchi S, and Yoshida M. 14-3-3 regulates the nuclear import of class IIa histone deacetylases. Biochem Biophys Res Commun 377: 852-856, 2008.
126. Noro R, Gemma A, Miyanaga A, Kosaihira S, Minegishi Y, Nara M, Kokubo Y, Seike M, Kataoka K, Matsuda K, Okano T, Yoshimura A, and Kudoh S. PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Oncol 31: 1157-1163, 2007.
127. Ojuka EO, Goyaram V, and Smith JA. The role of CaMKII in regulating GLUT4 expression in skeletal muscle. Am J Physiol Endocrinol Metab 303: E322-E331, 2012.
128. Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK, and Furnari FB. PCAF modulates PTEN activity. J Biol Chem 281: 26562-26568, 2006.
129. Osoata GO, Yamamura S, Ito M, Vuppusetty C, Adcock IM, Barnes PJ, and Ito K. Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. Biochem Biophys Res Commun 384: 366-371, 2009.
130. Ouyang H, Ali YO, Ravichandran M, Dong A, Qiu W, MacKenzie F, Dhe-Paganon S, Arrowsmith CH, and Zhai RG. Protein aggregates are recruited to aggresome by histone deacetylase 6 via unanchored ubiquitin C termini. J Biol Chem 287: 2317-2327, 2011.
131. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, Jiang S, Gilliland DG, Chin L, Wong WH, Castrillon DH, and DePinho RA. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128: 309-323, 2007.
132. Pan L, Lu J, Wang X, Han L, Zhang Y, Han S, and Huang B. Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression. Cancer 109: 1676-1688, 2007.
133. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, Mullighan CG, Gaidano G, Rabadan R, Brindle PK, and Dalla-Favera R. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471: 189-195, 2011.
134. Perez-Perri JI, Acevedo JM, and Wappner P. Epigenetics: new questions on the response to hypoxia. Int J Mol Sci 12: 4705-4721, 2011.
135. Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, Kultz D, and Weiss RH. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 5: 64, 2006.
136. Petrie K, Guidez F, Howell L, Healy L, Waxman S, Greaves M, and Zelent A. The histone deacetylase 9 gene encodes multiple protein isoforms. J Biol Chem 278: 16059-16072, 2003.
137. Pham TX and Lee J. Dietary regulation of histone acetylases and deacetylases for the prevention of metabolic diseases. Nutrients 4: 1868-1886, 2012.
138. Platten M, Wick W, and Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 72: 5435-5440, 2012.
139. Pluemsampant S, Safronova OS, Nakahama K, and Morita I. Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors. Int J Cancer 122: 333-341, 2008.
140. Ponnusamy S, Meyers-Needham M, Senkal CE, Saddoughi SA, Sentelle D, Selvam SP, Salas A, and Ogretmen B. Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol 6: 1603-1624, 2012.
141. Prins ML. Cerebral metabolic adaptation and ketone metabolism after brain injury. J Cereb Blood Flow Metab 28: 1-16, 2008.
142. Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, and Golemis EA. HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell 129: 1351-1363, 2007.
143. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, and Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434: 113-118, 2005.
144. Ropero S and Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1: 19-25, 2007.
145. Saha RN and Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ 13: 539-550, 2006.
146. Sahlin K, Harris RC, Nylind B, and Hultman E. Lactate content and pH in muscle obtained after dynamic exercise. Pflugers Arch 367: 143-149, 1976.
147. Schulz TJ, Thierbach R, Voigt A, Drewes G, Mietzner B, Steinberg P, Pfeiffer AF, and Ristow M. Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. J Biol Chem 281: 977-981, 2006.
148. Schwer B and Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell Metab 7: 104-112, 2008.
149. Scott FL, Fuchs GJ, Boyd SE, Denault JB, Hawkins CJ, Dequiedt F, and Salvesen GS. Caspase-8 cleaves histone deacetylase 7 and abolishes its transcription repressor function. J Biol Chem 283: 19499-19510, 2008.
150. Segre CV and Chiocca S. Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2. J Biomed Biotechnol 2011: 690848, 2011.
151. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
152. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634, 2010.
153. Sha Y and Marshall HE. S-nitrosylation in the regulation of gene transcription. Biochim Biophys Acta 1820: 701-711, 2012.
154. Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, Grueter CA, Lim H, Saunders LR, Stevens RD, Newgard CB, Farese RV, Jr., de Cabo R, Ulrich S, Akassoglou K, and Verdin E. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339: 211-214, 2013.
155. Song MS, Salmena L, and Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13: 283-296, 2012.
156. Sucharov CC, Dockstader K, and McKinsey TA. YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5. Mol Biol Cell 19: 4141-4153, 2008.
157. Sun Z, Miller RA, Patel RT, Chen J, Dhir R, Wang H, Zhang D, Graham MJ, Unterman TG, Shulman GI, Sztalryd C, Bennett MJ, Ahima RS, Birnbaum MJ, and Lazar MA. Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat Med 18: 934-942, 2012.
158. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y, Sugano S, Sato E, Nagao T, Yokote K, Tatsuno I, and Prives C. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A 107: 7461-7466, 2010.
159. Takami Y and Nakayama T. N-terminal region, C-terminal region, nuclear export signal, and deacetylation activity of histone deacetylase-3 are essential for the viability of the DT40 chicken B cell line. J Biol Chem 275: 16191-16201, 2000.
160. Takemori H, Katoh Hashimoto Y, Nakae J, Olson EN, and Okamoto M. Inactivation of HDAC5 by SIK1 in AICAR-treated C2C12 myoblasts. Endocr J 56: 121-130, 2009.
161. Tammineni P, Anugula C, Mohammed F, Anjaneyulu M, Larner AC, and Sepuri NB. The import of the transcription factor STAT3 into mitochondria depends on GRIM-19, a component of the electron transport chain. J Biol Chem 288: 4723-4732, 2013.
162. Tanoue S, Uto H, Kumamoto R, Arima S, Hashimoto S, Nasu Y, Takami Y, Moriuchi A, Sakiyama T, Oketani M, Ido A, and Tsubouchi H. Liver regeneration after partial hepatectomy in rat is more impaired in a steatotic liver induced by dietary fructose compared to dietary fat. Biochem Biophys Res Commun 407: 163-168, 2011.
163. This reference has been deleted.
164. Taylor SS, Buechler JA, and Yonemoto W. cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu Rev Biochem 59: 971-1005, 1990.
165. Thangaraju M, Carswell KN, Prasad PD, and Ganapathy V. Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem J 417: 379-389, 2009.
166. van der Heide LP and Smidt MP. Regulation of FoxO activity by CBP/p300-mediated acetylation. Trends Biochem Sci 30: 81-86, 2005.
167. Vervoorts J, Luscher-Firzlaff JM, Rottmann S, Lilischkis R, Walsemann G, Dohmann K, Austen M, and Luscher B. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep 4: 484-490, 2003.
168. Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, Wright KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E, and Sotomayor EM. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 10: 92-100, 2009.
169. Vogelauer M, Krall AS, McBrian MA, Li JY, and Kurdistani SK. Stimulation of histone deacetylase activity by metabolites of intermediary metabolism. J Biol Chem 287: 32006-32016, 2012.
170. Wagner JM, Hackanson B, Lubbert M, and Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 1: 117-136, 2010.
171. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, and Mueller-Klieser W. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 60: 916-921, 2000.
172. Waltregny D, De Leval L, Glenisson W, Ly Tran S, North BJ, Bellahcene A, Weidle U, Verdin E, and Castronovo V. Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Am J Pathol 165: 553-564, 2004.
173. Wang F, Chan CH, Chen K, Guan X, Lin HK, and Tong Q. Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene 31: 1546-1557, 2012.
174. Wang GL, Salisbury E, Shi X, Timchenko L, Medrano EE, and Timchenko NA. HDAC1 cooperates with C/EBPalpha in the inhibition of liver proliferation in old mice. J Biol Chem 283: 26169-26178, 2008.
175. Wang Q, Bailey CG, Ng C, Tiffen J, Thoeng A, Minhas V, Lehman ML, Hendy SC, Buchanan G, Nelson CC, Rasko JE, and Holst J. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res 71: 7525-7536, 2011.
176. Wang Q, Zhang Y, Yang C, Xiong H, Lin Y, Yao J, Li H, Xie L, Zhao W, Yao Y, Ning ZB, Zeng R, Xiong Y, Guan KL, Zhao S, and Zhao GP. Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science 327: 1004-1007, 2010.
177. Wardell SE, Ilkayeva OR, Wieman HL, Frigo DE, Rathmell JC, Newgard CB, and McDonnell DP. Glucose metabolism as a target of histone deacetylase inhibitors. Mol Endocrinol 23: 388-401, 2009.
178. Watabe M and Nakaki T. CK2 as anti-stress factor. Commun Integr Biol 5: 278-280, 2012.
179. Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, Koeck T, Derecka M, Szczepanek K, Szelag M, Gornicka A, Moh A, Moghaddas S, Chen Q, Bobbili S, Cichy J, Dulak J, Baker DP, Wolfman A, Stuehr D, Hassan MO, Fu XY, Avadhani N, Drake JI, Fawcett P, Lesnefsky EJ, and Larner AC. Function of mitochondrial Stat3 in cellular respiration. Science 323: 793-797, 2009.
180. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, and Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324: 1076-1080, 2009.
181. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, and Thompson CB. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 105: 18782-18787, 2008.
182. Wise DR and Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35: 427-433, 2010.
183. Witt O, Deubzer HE, Milde T, and Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett 277: 8-21, 2009.
184. Wolfson NA, Ann Pitcairn C, and Fierke CA. HDAC8 substrates: histones and beyond. Biopolymers 99: 112-126, 2013.
185. Wu S, Kasim V, Kano MR, Tanaka S, Ohba S, Miura Y, Miyata K, Liu X, Matsuhashi A, Chung UI, Yang L, Kataoka K, Nishiyama N, and Miyagishi M. Transcription factor YY1 contributes to tumor growth by stabilizing hypoxia factor HIF-1alpha in a p53-independent manner. Cancer Res 73: 1787-1799, 2013.
186. Wu WS, Vallian S, Seto E, Yang WM, Edmondson D, Roth S, and Chang KS. The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol Cell Biol 21: 2259-2268, 2001.
187. Yang L, Vaitheesvaran B, Hartil K, Robinson AJ, Hoopmann MR, Eng JK, Kurland IJ, and Bruce JE. The fasted/fed mouse metabolic acetylome: N6-acetylation differences suggest acetylation coordinates organ-specific fuel switching. J Proteome Res 10: 4134-4149, 2011.
188. Yang T, Jian W, Luo Y, Fu X, Noguchi C, Bungert J, Huang S, and Qiu Y. Acetylation of histone deacetylase 1 regulates NuRD corepressor complex activity. J Biol Chem 287: 40279-40291, 2012.
189. Yang W and Lu Z. Regulation and function of pyruvate kinase M2 in cancer. Cancer Lett 339: 153-158, 2013.
190. Yang WM, Tsai SC, Wen YD, Fejer G, and Seto E. Functional domains of histone deacetylase-3. J Biol Chem 277: 9447-9454, 2002.
191. Yang XJ and Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 9: 206-218, 2008.
192. Yao YL, Yang WM, and Seto E. Regulation of transcription factor YY1 by acetylation and deacetylation. Mol Cell Biol 21: 5979-5991, 2001.
193. Ye J, Mancuso A, Tong X, Ward PS, Fan J, Rabinowitz JD, and Thompson CB. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci U S A 109: 6904-6909, 2012.
194. Yoo YG, Kong G, and Lee MO. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO J 25: 1231-1241, 2006.
195. Yuan ZL, Guan YJ, Chatterjee D, and Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307: 269-273, 2005.
196. Zentner GE and Henikoff S. Regulation of nucleosome dynamics by histone modifications. Nat Struct Mol Biol 20: 259-266, 2013.
197. Zhang J, Kan S, Huang B, Hao Z, Mak TW, and Zhong Q. Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2. Genes Dev 25: 2610-2618, 2011.
198. Zhang X, Ozawa Y, Lee H, Wen YD, Tan TH, Wadzinski BE, and Seto E. Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev 19: 827-839, 2005.
199. Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J, Olashaw N, Parsons JT, Yang XJ, Dent SR, Yao TP, Lane WS, and Seto E. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 27: 197-213, 2007.
200. Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M, Cao C, Li N, Cheng HL, Chua K, Lombard D, Mizeracki A, Matthias G, Alt FW, Khochbin S, and Matthias P. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 28: 1688-1701, 2008.
201. Zhou G, Sebhat IK, and Zhang BB. AMPK activators - potential therapeutics for metabolic and other diseases. Acta Physiol (Oxf) 196: 175-190, 2009.